News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Subscribe To Our Newsletter & Stay Updated
